IsoRay Announces Its Addition to the Russell Microcap Index
June 30 2014 - 8:45AM
Marketwired
IsoRay Announces Its Addition to the Russell Microcap Index
RICHLAND, WA--(Marketwired - Jun 30, 2014) - IsoRay, Inc.
(NYSEMKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for cancers of
the brain, lung, head and neck, prostate and gynecologic ("gyn"),
today announced that it has been added to the Russell Microcap
Index.
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. Russell determines membership for its
equity indexes primarily by objective market-capitalization
rankings and style attributes.
IsoRay Chairman and CEO Dwight Babcock commented, "Being
included in the Russell Microcap Index represents an important
milestone for IsoRay that we expect will increase shareholder
awareness of our accomplishments. This follows several other recent
milestones for IsoRay, including our newest product, Liquid
Cesium-131, being FDA cleared, our first patient being treated
using GliaSite with liquid cesium-131 and a peer reviewed
publication on the success of using IsoRay's Cesium-131 seed in
treating gynecologic cancers."
About Russell
Russell Investments (Russell) is a global asset manager and one
of only a few firms that offer activity managed multi-asset
portfolios and services that include advice, investments and
implementation. Russell stands with institutional investors,
financial advisers and individuals working with their advisers --
using the firm's core capabilities that extend across capital
market insights, manager research, portfolio construction,
portfolio implementation and indexes to help each achieve their
desired investment outcomes.
About IsoRay IsoRay, Inc., through its subsidiary, IsoRay
Medical, Inc., is the sole producer of Cesium-131 brachytherapy
seeds, which is expanding brachytherapy options throughout the
body. Learn more about this innovative Richland, Washington company
and explore the many benefits and uses of GliaSite® and Cesium-131
by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us
on Twitter@Isoray.
Safe Harbor Statement Statements in this news release about
IsoRay's future expectations, including: the advantages of our
products and their delivery systems, whether inclusion of IsoRay in
the Russell Microcap Index will increase shareholder awareness of
IsoRay's accomplishments, and all other statements in this release,
other than historical facts, are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 ("PSLRA"). This statement is included for the express
purpose of availing IsoRay, Inc. of the protections of the safe
harbor provisions of the PSLRA. It is important to note that
actual results and ultimate corporate actions could differ
materially from those in such forward-looking statements based on
such factors as physician acceptance, training and use of IsoRay's
products, changing levels of demand for IsoRay's current and
proposed future products, IsoRay's ability to reduce or maintain
expenses while increasing sales, whether additional studies are
released and support the conclusions of past studies, patient
results achieved with our products, successful completion of future
research and development activities, our ability of our
distributors and customers to receive and maintain all required
regulatory approvals in the U.S. and internationally, continued
compliance with ISO standards as audited by BSI, the success of our
sales and marketing efforts, IsoRay's ability to successfully
manufacture, market and sell its products, whether institutions
will receive all required state, federal and foreign regulatory
approvals and licenses to use IsoRay's products, IsoRay's
ability to manufacture its products in sufficient quantities to
meet demand within required delivery time periods while meeting its
quality control standards, IsoRay's ability to enforce its
intellectual property rights, changes in reimbursement rates,
changes in laws and regulations applicable to our products, whether
IsoRay will continue to be included in the Russell Microcap Index,
and other risks detailed from time to time in IsoRay's reports
filed with the SEC.
CONTACT: IsoRay Medical Info@Isoray.com (509) 375-1202 Or
Worldwide Financial Info@wwfinancial.com (954) 360-9998
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2024 to May 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From May 2023 to May 2024